 | • レポートコード：QYR2104Z4116 • 出版社/出版日：QYResearch / 2021年4月10日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、次世代抗体療法のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（抗体薬物複合体（ADC）、二重特異性抗体（BsAbs）、Fc操作抗体、抗体フラグメント＆抗体様タンパク質（AF＆ALP）、生体類似抗体（Ab）製品）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・次世代抗体療法の市場動向 ・企業の競争状況、市場シェア ・次世代抗体療法の種類別市場規模（抗体薬物複合体（ADC）、二重特異性抗体（BsAbs）、Fc操作抗体、抗体フラグメント＆抗体様タンパク質（AF＆ALP）、生体類似抗体（Ab）製品） ・次世代抗体療法の用途別市場規模（病院、診療所、その他） ・次世代抗体療法の北米市場規模2016-2027（アメリカ、カナダ） ・次世代抗体療法のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・次世代抗体療法のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・次世代抗体療法の中南米市場規模2016-2027（メキシコ、ブラジル） ・次世代抗体療法の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer、Roche、Bristol-Myers Squibb、Amgen、AstraZeneca、Bayer、Takeda Pharmaceuticals、Biogen、Seattle Genetics、ImmunoGen、Kyowa Hakko Kirin、Xencor、Dyax Corp） ・結論 |
The ADCs segment held the largest market share in the historical period and is projected to hold a market share of over 50% by 2025. The Fc engineered antibodies segmented is projected to witness the fastest growth during the forecast period.
Market Analysis and Insights: Global Next Generation Antibody Therapeutics Market
The global Next Generation Antibody Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Next Generation Antibody Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Next Generation Antibody Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Next Generation Antibody Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Next Generation Antibody Therapeutics market.
Global Next Generation Antibody Therapeutics Scope and Market Size
Next Generation Antibody Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Next Generation Antibody Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Antibody Drug Conjugates (ADCs)
Bispecific Antibodies (BsAbs)
Fc Engineered Antibodies
Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
Biosimilar Antibody (Ab) Products
Segment by Application
Hospitals
Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Pfizer
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Bayer
Takeda Pharmaceuticals
Biogen
Seattle Genetics
Amgen
AstraZeneca
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Antibody Drug Conjugates (ADCs)
1.2.3 Bispecific Antibodies (BsAbs)
1.2.4 Fc Engineered Antibodies
1.2.5 Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
1.2.6 Biosimilar Antibody (Ab) Products
1.3 Market by Application
1.3.1 Global Next Generation Antibody Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Next Generation Antibody Therapeutics Market Perspective (2016-2027)
2.2 Next Generation Antibody Therapeutics Growth Trends by Regions
2.2.1 Next Generation Antibody Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Next Generation Antibody Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Next Generation Antibody Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Next Generation Antibody Therapeutics Industry Dynamic
2.3.1 Next Generation Antibody Therapeutics Market Trends
2.3.2 Next Generation Antibody Therapeutics Market Drivers
2.3.3 Next Generation Antibody Therapeutics Market Challenges
2.3.4 Next Generation Antibody Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next Generation Antibody Therapeutics Players by Revenue
3.1.1 Global Top Next Generation Antibody Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Next Generation Antibody Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Next Generation Antibody Therapeutics Revenue
3.4 Global Next Generation Antibody Therapeutics Market Concentration Ratio
3.4.1 Global Next Generation Antibody Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next Generation Antibody Therapeutics Revenue in 2020
3.5 Next Generation Antibody Therapeutics Key Players Head office and Area Served
3.6 Key Players Next Generation Antibody Therapeutics Product Solution and Service
3.7 Date of Enter into Next Generation Antibody Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Next Generation Antibody Therapeutics Breakdown Data by Type
4.1 Global Next Generation Antibody Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2022-2027)
5 Next Generation Antibody Therapeutics Breakdown Data by Application
5.1 Global Next Generation Antibody Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Next Generation Antibody Therapeutics Market Size (2016-2027)
6.2 North America Next Generation Antibody Therapeutics Market Size by Type
6.2.1 North America Next Generation Antibody Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Next Generation Antibody Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Next Generation Antibody Therapeutics Market Size by Type (2016-2027)
6.3 North America Next Generation Antibody Therapeutics Market Size by Application
6.3.1 North America Next Generation Antibody Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Next Generation Antibody Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Next Generation Antibody Therapeutics Market Size by Application (2016-2027)
6.4 North America Next Generation Antibody Therapeutics Market Size by Country
6.4.1 North America Next Generation Antibody Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Next Generation Antibody Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Next Generation Antibody Therapeutics Market Size (2016-2027)
7.2 Europe Next Generation Antibody Therapeutics Market Size by Type
7.2.1 Europe Next Generation Antibody Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Next Generation Antibody Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Next Generation Antibody Therapeutics Market Size by Type (2016-2027)
7.3 Europe Next Generation Antibody Therapeutics Market Size by Application
7.3.1 Europe Next Generation Antibody Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Next Generation Antibody Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Next Generation Antibody Therapeutics Market Size by Application (2016-2027)
7.4 Europe Next Generation Antibody Therapeutics Market Size by Country
7.4.1 Europe Next Generation Antibody Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Next Generation Antibody Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type
8.2.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application
8.3.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region
8.4.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Next Generation Antibody Therapeutics Market Size (2016-2027)
9.2 Latin America Next Generation Antibody Therapeutics Market Size by Type
9.2.1 Latin America Next Generation Antibody Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Next Generation Antibody Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Next Generation Antibody Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Next Generation Antibody Therapeutics Market Size by Application
9.3.1 Latin America Next Generation Antibody Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Next Generation Antibody Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Next Generation Antibody Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Next Generation Antibody Therapeutics Market Size by Country
9.4.1 Latin America Next Generation Antibody Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Next Generation Antibody Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type
10.2.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application
10.3.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country
10.4.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Next Generation Antibody Therapeutics Introduction
11.1.4 Pfizer Revenue in Next Generation Antibody Therapeutics Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Next Generation Antibody Therapeutics Introduction
11.2.4 Roche Revenue in Next Generation Antibody Therapeutics Business (2016-2021)
11.2.5 Roche Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Next Generation Antibody Therapeutics Introduction
11.3.4 Bristol-Myers Squibb Revenue in Next Generation Antibody Therapeutics Business (2016-2021)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 Amgen
11.4.1 Amgen Company Details
11.4.2 Amgen Business Overview
11.4.3 Amgen Next Generation Antibody Therapeutics Introduction
11.4.4 Amgen Revenue in Next Generation Antibody Therapeutics Business (2016-2021)
11.4.5 Amgen Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Next Generation Antibody Therapeutics Introduction
11.5.4 AstraZeneca Revenue in Next Generation Antibody Therapeutics Business (2016-2021)
11.5.5 AstraZeneca Recent Development
11.6 Bayer
11.6.1 Bayer Company Details
11.6.2 Bayer Business Overview
11.6.3 Bayer Next Generation Antibody Therapeutics Introduction
11.6.4 Bayer Revenue in Next Generation Antibody Therapeutics Business (2016-2021)
11.6.5 Bayer Recent Development
11.7 Takeda Pharmaceuticals
11.7.1 Takeda Pharmaceuticals Company Details
11.7.2 Takeda Pharmaceuticals Business Overview
11.7.3 Takeda Pharmaceuticals Next Generation Antibody Therapeutics Introduction
11.7.4 Takeda Pharmaceuticals Revenue in Next Generation Antibody Therapeutics Business (2016-2021)
11.7.5 Takeda Pharmaceuticals Recent Development
11.8 Biogen
11.8.1 Biogen Company Details
11.8.2 Biogen Business Overview
11.8.3 Biogen Next Generation Antibody Therapeutics Introduction
11.8.4 Biogen Revenue in Next Generation Antibody Therapeutics Business (2016-2021)
11.8.5 Biogen Recent Development
11.9 Seattle Genetics
11.9.1 Seattle Genetics Company Details
11.9.2 Seattle Genetics Business Overview
11.9.3 Seattle Genetics Next Generation Antibody Therapeutics Introduction
11.9.4 Seattle Genetics Revenue in Next Generation Antibody Therapeutics Business (2016-2021)
11.9.5 Seattle Genetics Recent Development
11.10 ImmunoGen
11.10.1 ImmunoGen Company Details
11.10.2 ImmunoGen Business Overview
11.10.3 ImmunoGen Next Generation Antibody Therapeutics Introduction
11.10.4 ImmunoGen Revenue in Next Generation Antibody Therapeutics Business (2016-2021)
11.10.5 ImmunoGen Recent Development
11.11 Kyowa Hakko Kirin
11.11.1 Kyowa Hakko Kirin Company Details
11.11.2 Kyowa Hakko Kirin Business Overview
11.11.3 Kyowa Hakko Kirin Next Generation Antibody Therapeutics Introduction
11.11.4 Kyowa Hakko Kirin Revenue in Next Generation Antibody Therapeutics Business (2016-2021)
11.11.5 Kyowa Hakko Kirin Recent Development
11.12 Xencor
11.12.1 Xencor Company Details
11.12.2 Xencor Business Overview
11.12.3 Xencor Next Generation Antibody Therapeutics Introduction
11.12.4 Xencor Revenue in Next Generation Antibody Therapeutics Business (2016-2021)
11.12.5 Xencor Recent Development
11.13 Dyax Corp
11.13.1 Dyax Corp Company Details
11.13.2 Dyax Corp Business Overview
11.13.3 Dyax Corp Next Generation Antibody Therapeutics Introduction
11.13.4 Dyax Corp Revenue in Next Generation Antibody Therapeutics Business (2016-2021)
11.13.5 Dyax Corp Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Antibody Drug Conjugates (ADCs)
Table 3. Key Players of Bispecific Antibodies (BsAbs)
Table 4. Key Players of Fc Engineered Antibodies
Table 5. Key Players of Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
Table 6. Key Players of Biosimilar Antibody (Ab) Products
Table 7. Global Next Generation Antibody Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Next Generation Antibody Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Next Generation Antibody Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Next Generation Antibody Therapeutics Market Share by Regions (2016-2021)
Table 11. Global Next Generation Antibody Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Next Generation Antibody Therapeutics Market Share by Regions (2022-2027)
Table 13. Next Generation Antibody Therapeutics Market Trends
Table 14. Next Generation Antibody Therapeutics Market Drivers
Table 15. Next Generation Antibody Therapeutics Market Challenges
Table 16. Next Generation Antibody Therapeutics Market Restraints
Table 17. Global Next Generation Antibody Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Next Generation Antibody Therapeutics Market Share by Players (2016-2021)
Table 19. Global Top Next Generation Antibody Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Next Generation Antibody Therapeutics as of 2020)
Table 20. Ranking of Global Top Next Generation Antibody Therapeutics Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Next Generation Antibody Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Next Generation Antibody Therapeutics Product Solution and Service
Table 24. Date of Enter into Next Generation Antibody Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Next Generation Antibody Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Next Generation Antibody Therapeutics Revenue Market Share by Type (2016-2021)
Table 28. Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Next Generation Antibody Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Next Generation Antibody Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Next Generation Antibody Therapeutics Revenue Market Share by Application (2016-2021)
Table 32. Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Next Generation Antibody Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Next Generation Antibody Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Next Generation Antibody Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Next Generation Antibody Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Next Generation Antibody Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Next Generation Antibody Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Next Generation Antibody Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Next Generation Antibody Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Next Generation Antibody Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Next Generation Antibody Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Next Generation Antibody Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Next Generation Antibody Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Next Generation Antibody Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Next Generation Antibody Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Next Generation Antibody Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Next Generation Antibody Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Next Generation Antibody Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Next Generation Antibody Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Next Generation Antibody Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 64. Pfizer Company Details
Table 65. Pfizer Business Overview
Table 66. Pfizer Next Generation Antibody Therapeutics Product
Table 67. Pfizer Revenue in Next Generation Antibody Therapeutics Business (2016-2021) & (US$ Million)
Table 68. Pfizer Recent Development
Table 69. Roche Company Details
Table 70. Roche Business Overview
Table 71. Roche Next Generation Antibody Therapeutics Product
Table 72. Roche Revenue in Next Generation Antibody Therapeutics Business (2016-2021) & (US$ Million)
Table 73. Roche Recent Development
Table 74. Bristol-Myers Squibb Company Details
Table 75. Bristol-Myers Squibb Business Overview
Table 76. Bristol-Myers Squibb Next Generation Antibody Therapeutics Product
Table 77. Bristol-Myers Squibb Revenue in Next Generation Antibody Therapeutics Business (2016-2021) & (US$ Million)
Table 78. Bristol-Myers Squibb Recent Development
Table 79. Amgen Company Details
Table 80. Amgen Business Overview
Table 81. Amgen Next Generation Antibody Therapeutics Product
Table 82. Amgen Revenue in Next Generation Antibody Therapeutics Business (2016-2021) & (US$ Million)
Table 83. Amgen Recent Development
Table 84. AstraZeneca Company Details
Table 85. AstraZeneca Business Overview
Table 86. AstraZeneca Next Generation Antibody Therapeutics Product
Table 87. AstraZeneca Revenue in Next Generation Antibody Therapeutics Business (2016-2021) & (US$ Million)
Table 88. AstraZeneca Recent Development
Table 89. Bayer Company Details
Table 90. Bayer Business Overview
Table 91. Bayer Next Generation Antibody Therapeutics Product
Table 92. Bayer Revenue in Next Generation Antibody Therapeutics Business (2016-2021) & (US$ Million)
Table 93. Bayer Recent Development
Table 94. Takeda Pharmaceuticals Company Details
Table 95. Takeda Pharmaceuticals Business Overview
Table 96. Takeda Pharmaceuticals Next Generation Antibody Therapeutics Product
Table 97. Takeda Pharmaceuticals Revenue in Next Generation Antibody Therapeutics Business (2016-2021) & (US$ Million)
Table 98. Takeda Pharmaceuticals Recent Development
Table 99. Biogen Company Details
Table 100. Biogen Business Overview
Table 101. Biogen Revenue in Next Generation Antibody Therapeutics Business (2016-2021) & (US$ Million)
Table 102. Biogen Recent Development
Table 103. Seattle Genetics Company Details
Table 104. Seattle Genetics Business Overview
Table 105. Seattle Genetics Next Generation Antibody Therapeutics Product
Table 106. Seattle Genetics Revenue in Next Generation Antibody Therapeutics Business (2016-2021) & (US$ Million)
Table 107. Seattle Genetics Recent Development
Table 108. ImmunoGen Company Details
Table 109. ImmunoGen Business Overview
Table 110. ImmunoGen Next Generation Antibody Therapeutics Product
Table 111. ImmunoGen Revenue in Next Generation Antibody Therapeutics Business (2016-2021) & (US$ Million)
Table 112. ImmunoGen Recent Development
Table 113. Kyowa Hakko Kirin Company Details
Table 114. Kyowa Hakko Kirin Business Overview
Table 115. Kyowa Hakko Kirin Next Generation Antibody Therapeutics Product
Table 116. Kyowa Hakko Kirin Revenue in Next Generation Antibody Therapeutics Business (2016-2021) & (US$ Million)
Table 117. Kyowa Hakko Kirin Recent Development
Table 118. Xencor Company Details
Table 119. Xencor Business Overview
Table 120. Xencor Next Generation Antibody Therapeutics Product
Table 121. Xencor Revenue in Next Generation Antibody Therapeutics Business (2016-2021) & (US$ Million)
Table 122. Xencor Recent Development
Table 123. Dyax Corp Company Details
Table 124. Dyax Corp Business Overview
Table 125. Dyax Corp Next Generation Antibody Therapeutics Product
Table 126. Dyax Corp Revenue in Next Generation Antibody Therapeutics Business (2016-2021) & (US$ Million)
Table 127. Dyax Corp Recent Development
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Next Generation Antibody Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Antibody Drug Conjugates (ADCs) Features
Figure 3. Bispecific Antibodies (BsAbs) Features
Figure 4. Fc Engineered Antibodies Features
Figure 5. Antibody Fragments and Antibody-Like Proteins (AF & ALPs) Features
Figure 6. Biosimilar Antibody (Ab) Products Features
Figure 7. Global Next Generation Antibody Therapeutics Market Share by Application: 2020 VS 2027
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Others Case Studies
Figure 11. Next Generation Antibody Therapeutics Report Years Considered
Figure 12. Global Next Generation Antibody Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Next Generation Antibody Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Next Generation Antibody Therapeutics Market Share by Regions: 2020 VS 2027
Figure 15. Global Next Generation Antibody Therapeutics Market Share by Regions (2022-2027)
Figure 16. Global Next Generation Antibody Therapeutics Market Share by Players in 2020
Figure 17. Global Top Next Generation Antibody Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Next Generation Antibody Therapeutics as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Next Generation Antibody Therapeutics Revenue in 2020
Figure 19. Global Next Generation Antibody Therapeutics Revenue Market Share by Type (2016-2021)
Figure 20. Global Next Generation Antibody Therapeutics Revenue Market Share by Type (2022-2027)
Figure 21. North America Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Next Generation Antibody Therapeutics Market Share by Type (2016-2027)
Figure 23. North America Next Generation Antibody Therapeutics Market Share by Application (2016-2027)
Figure 24. North America Next Generation Antibody Therapeutics Market Share by Country (2016-2027)
Figure 25. United States Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Next Generation Antibody Therapeutics Market Share by Type (2016-2027)
Figure 29. Europe Next Generation Antibody Therapeutics Market Share by Application (2016-2027)
Figure 30. Europe Next Generation Antibody Therapeutics Market Share by Country (2016-2027)
Figure 31. Germany Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Next Generation Antibody Therapeutics Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Next Generation Antibody Therapeutics Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Next Generation Antibody Therapeutics Market Share by Region (2016-2027)
Figure 41. China Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Next Generation Antibody Therapeutics Market Share by Type (2016-2027)
Figure 49. Latin America Next Generation Antibody Therapeutics Market Share by Application (2016-2027)
Figure 50. Latin America Next Generation Antibody Therapeutics Market Share by Country (2016-2027)
Figure 51. Mexico Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Next Generation Antibody Therapeutics Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Next Generation Antibody Therapeutics Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Next Generation Antibody Therapeutics Market Share by Country (2016-2027)
Figure 57. Turkey Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Next Generation Antibody Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Pfizer Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2016-2021)
Figure 61. Roche Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2016-2021)
Figure 62. Bristol-Myers Squibb Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2016-2021)
Figure 63. Amgen Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2016-2021)
Figure 64. AstraZeneca Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2016-2021)
Figure 65. Bayer Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2016-2021)
Figure 66. Takeda Pharmaceuticals Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2016-2021)
Figure 67. Biogen Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2016-2021)
Figure 68. Seattle Genetics Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2016-2021)
Figure 69. ImmunoGen Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2016-2021)
Figure 70. Kyowa Hakko Kirin Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2016-2021)
Figure 71. Xencor Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2016-2021)
Figure 72. Dyax Corp Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2016-2021)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed